# Jerry McMahon

> Dr. Jerry McMahon is the President and CEO of STORM Therapeutics, a Cambridge, UK biotech pioneering drugs that target RNA modifying enzymes. A biochemist-turned-operator with more than 30 years in oncology drug development, he has led biotechs from bench to IPO, helped bring the cancer drug sunitinib (Sutent) to patients, and now steers STORM's first-in-class METTL3 inhibitor STC-15 through the clinic - the first RNA modification enzyme inhibitor ever to enter human trials.

- **Role:** President and CEO at STORM Therapeutics
- **Organizations:** STORM Therapeutics, Harpoon Therapeutics, Kolltan Pharmaceuticals, MedImmune (AstraZeneca), SUGEN (Pharmacia/Pfizer)
- **Nationality:** American
- **Education:** BS in Biology, Rensselaer Polytechnic Institute, PhD in Biochemistry and Genetics, Rensselaer Polytechnic Institute
- **Known for:** Author of more than 100 scientific and medical publications, Inventor on more than 60 US patents, Built Harpoon Therapeutics from early stage through a Nasdaq IPO

## Career timeline

- **1990s** — President at SUGEN (later Pharmacia/Pfizer), instrumental in developing sunitinib (Sutent)
- **2000s** — Senior Vice President, Oncology at MedImmune (AstraZeneca)
- **2010s** — President and CEO of Kolltan Pharmaceuticals, acquired by Celldex
- **2016** — Appointed President and CEO of Harpoon Therapeutics
- **2016-2021** — Built Harpoon Therapeutics from early stage through Nasdaq IPO, follow-on financings and collaborations
- **2022** — Appointed President, CEO and Board Director of STORM Therapeutics (September)
- **2024** — STORM presents final Phase 1 data on METTL3 inhibitor STC-15 at SITC
- **2025** — STORM initiates Phase 1b/2 study of STC-15 with LOQTORZI (toripalimab); appoints new CMO

## Achievements

- Author of more than 100 scientific and medical publications
- Inventor on more than 60 US patents
- Built Harpoon Therapeutics from early stage through a Nasdaq IPO
- Instrumental in the development of sunitinib (Sutent) while President at SUGEN
- Held academic appointments at Yale Comprehensive Cancer Center, Tufts University School of Medicine and MIT
- Leading the first RNA modifying enzyme inhibitor (STC-15) ever to enter clinical development

## Latest updates

- **2024-11** — STORM presented final Phase 1 data on STC-15 at SITC 2024: well tolerated, tumor regressions at all doses, 9% overall response rate, 67% disease control rate across 42 patients.
- **2025-05** — STORM dosed first patient in a Phase 1b/2 combination study of STC-15 with the PD-1 inhibitor LOQTORZI (toripalimab) and appointed Atif Abbas, M.D., as Chief Medical Officer.

## Links

- Website: https://stormtherapeutics.com
- LinkedIn: http://www.linkedin.com/in/jerry-mcmahon-18252120
- Twitter/X: https://twitter.com/storm_tx

---

Profile page: https://yespress.io/jerry-mcmahon
Published by YesPress — https://yespress.io
Last updated: 2026-07-01